I8F-MC-GPIG - Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506082-60-00

Acronym

I8F-MC-GPIG

Enrollment

Registered

2024-01-02

Start date

2023-02-28

Completion date

Unknown

Last updated

2025-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

Brief summary

Change from Baseline in Kidney Oxygenation in Participants with or without T2D BOLD MRI (blood oxygenation-level dependent magnetic resonance imaging). [Time Frame: Baseline, Week 52]

Interventions

DRUGTIRZEPATIDE

DRUGPlacebo to match LY3298176

DRUGIOHEXOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Kidney Oxygenation in Participants with or without T2D BOLD MRI (blood oxygenation-level dependent magnetic resonance imaging). [Time Frame: Baseline, Week 52]	—

Countries

Austria, Denmark, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026